Overview Recent research demonstrates a critical insight that should reshape how individuals and organisations approach artificial intelligence: the timing, context, and intentionality behind AI use fundamentally determine whether these tools …

Indirect Treatment Comparisons in France: Why HAS Exposes the Limits of Multi-Market Evidence Strategies For over a decade, market access teams have observed a persistent pattern: indirect treatment comparisons (ITCs) …

A Structural Shift in Evidence Generation for Medicines and Medical Technologies The implementation of the EU Health Technology Assessment Regulation (HTAR, 2021/2282) marks a fundamental transition in how clinical and …

What It Is, How It Works, and What Success Actually Requires Introduction: The Hidden Architecture of French Reimbursement In France, a single institution holds the power to determine whether a …

DiappyMed and Sanofi Partnership: Transforming Digital Diabetes Care in France DiappyMed’s €5 million seed funding round and strategic partnership with pharmaceutical giant Sanofi represent a pivotal moment for digital therapeutics …

Comprehensive guide to DTx reimbursement in France. Learn how digital therapeutics (DTx) navigate CNEDiMTS evaluation, PECAN requirements, and scientific methodology standards for HAS approval. The Urgency of Securing HAS Approval …